Literature DB >> 19631096

In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing.

Vincent H Tam1, Kimberly R Ledesma, Amy N Schilling, Tze-Peng Lim, Zhe Yuan, Romi Ghose, Russell E Lewis.   

Abstract

We have previously demonstrated Pseudomonas aeruginosa resistance selection because of suboptimal carbapenem exposures in an in vitro infection model, but the in vivo relevance of the observations is not well established. In this study, we examined the impact of carbapenem exposures on resistance selection using a neutropenic murine pneumonia model. Neutropenic mice were infected with approximately 10(6) CFU of P. aeruginosa intratracheally. Ten animals each were treated with 400 or 50 mg/kg of meropenem intraperitoneally or placebo every 8 h, given 2 h after infection for 2 to 4 days. Quantitative assessment of bacterial burden in lung tissues was performed at baseline, upon death, or at the end of experiment. Meropenem (400 mg/kg) offered a significant survival benefit, but selective amplification of the OprD(-) mutant population in lung tissue was observed in 20% to 30% of the animals. Our data suggested that suboptimal meropenem exposures might facilitate in vivo selection of resistance in a heterogeneous P. aeruginosa population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19631096     DOI: 10.1016/j.diagmicrobio.2009.03.031

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model.

Authors:  Jian Zhou; Kimberly R Ledesma; Kai-Tai Chang; Henrietta Abodakpi; Song Gao; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 2.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

3.  Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii.

Authors:  Dana R Bowers; Henry Cao; Jian Zhou; Kimberly R Ledesma; Dongxu Sun; Olga Lomovskaya; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

4.  Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.

Authors:  George Michail; Maria Labrou; Vassiliki Pitiriga; Styliani Manousaka; Nikolaos Sakellaridis; Athanasios Tsakris; Spyros Pournaras
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

5.  Relationship between Cefquinome PK/PD Parameters and Emergence of Resistance of Staphylococcus aureus in Rabbit Tissue-Cage Infection Model.

Authors:  Mingpeng Xiong; Xun Wu; Xiaomei Ye; Longfei Zhang; Shuyi Zeng; Zilong Huang; Yuzhi Wu; Jian Sun; Huanzhong Ding
Journal:  Front Microbiol       Date:  2016-06-07       Impact factor: 5.640

6.  Virulence of Acinetobacter baumannii Exhibiting Phenotypic Heterogeneous Growth against Meropenem in a Murine Thigh Infection Model.

Authors:  Evangelia Neou; George Michail; Athanassios Tsakris; Spyros Pournaras
Journal:  Antibiotics (Basel)       Date:  2013-03-11

7.  Importance of beta-lactam pharmacokinetics and pharmacodynamics on the recovery of microbial diversity in the airway of persons with cystic fibrosis.

Authors:  Andrea Hahn; Aszia Burrell; Hollis Chaney; Iman Sami; Anastassios C Koumbourlis; Robert J Freishtat; Edith T Zemanick; Stan Louie; Keith A Crandall
Journal:  J Investig Med       Date:  2021-05-21       Impact factor: 2.895

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.